In April 2015, I wrote a piece showing how Warren Buffett might look at Biogen (NASDAQ:BIIB). While the numbers for the biotech pharmaceutical company looked good, I stated at that time, "Based on this methodology, a good entry price would be $282, but given Biogen's current price of $430, it will be awhile before an opportunity should present itself. The current
